Research Peptides · Cat. 005-19
prepro-ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human)
Supplied as 200 µg per unit. Purity ≥ 95%. Molecular weight 3507.97. Species: Human. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | 005-19 |
|---|---|
| Product type | Research Peptides |
| Peptide family | Atrial Natriuretic Peptide (ANP) |
| Species | Human |
| Unit size | 200 µg |
| Molecular weight | 3507.97 Da |
| Purity | ≥ 95% |
| Validation | Exhibits correct molecular weight |
| Appearance | White powder |
| Contents | Each vial contains 200 µg of NET peptide. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. Cafforio P, Savonarola A, Stucci S, et al. J Bone Miner Res. 2014;29(1):55-66. Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in carcinoma cells. Manimala NJ, Frost CD, Lane ML, Higuera M, Beg R, Vesely DL. Eur J Clin Invest. 2013;43(11):1156-62. Central role of β-catenin in anticancer effects of cardiac hormones. Skelton WP, Skelton M, Vesely DL. Anticancer Res. 2013;33(6):2409-14. Four cardiac hormones eliminate 4-fold more human glioblastoma cells than the green mamba snake peptide. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR, Vesely DL. Cancer Lett. 2007;254(1):94-101. Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells. Vesely BA, Fitz SR, Gower WR, Vesely DL. Cancer Lett. 2006;233(2):226-31. Natriuretic peptide expression in the heart of the TTR-ANP transgenic mouse-Comparison to the normal heart. Lundberg S, Hansson M. Microsc Res Tech. 2005;68(2):97-106. Five cardiac hormones decrease the number of human small-cell lung cancer cells. Vesely BA, Song S, Sanchez-ramos J, et al. Eur J Clin Invest. 2005;35(6):388-98. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Yamamoto K, Burnett JC, Jougasaki M, et al. Hypertension. 1996;28(6):988-94. |
| Solubility | Insoluble in water. Dissolve in a small amount of DMSO or 60% acetonitrile in water with 0.1% TFA. Then dilute with water or any desired buffer. |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Sequence
Asn-Pro-Met-Tyr-Asn-Ala-Val-Ser-Asn-Ala-Asp-Leu-Met-Asp-Phe-Lys-Asn-Leu-Leu-Asp-His-Leu-Glu-Glu-Lys-Met-Pro-Leu-Glu-Asp
Storage & handling
Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
Confirm handling and preparation requirements against current product documentation and the requirements of your laboratory protocol.
Frequently asked
What is prepro-ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human)?
What purity is listed for 005-19?
How should prepro-ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human) be stored?
What is the sequence of prepro-ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human)?
What is the intended use of 005-19?
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.